Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 18/20 | 0.45 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9900606 | 0.92 | PLA2G7 (0.51) | PLA2G7DAOMEN1TNFPOLB | |
| SCHEMBL9900956 | 0.91 | PLA2G7 (0.43) | PLA2G7DAOMEN1TNFPOLB | |
| SCHEMBL9901506 | 0.87 | PLA2G7 (0.57) | PLA2G7 | |
| SCHEMBL9892573 | 0.86 | PLA2G7 (0.35) | PLA2G7MEN1TNFPOLBKMT2A | |
| SCHEMBL9901544 | 0.83 | DAO (0.45) | PLA2G7DAOMEN1TNFPOLB | |
| SCHEMBL9901970 | 0.82 | DAO (0.50) | PLA2G7DAOMEN1TNFPOLB | |
| SCHEMBL9900595 | 0.80 | TP53 (0.46) | DAOMEN1TNFPOLBKMT2A | |
| SCHEMBL9900537 | 0.80 | MEN1 (0.46) | PLA2G7DAOMEN1TNFPOLB | |
| SCHEMBL9900408 | 0.80 | PLA2G7 (0.56) | PLA2G7 | |
| SCHEMBL9901101 | 0.80 | PLA2G7 (0.53) | PLA2G7DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649053-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2 | Glaxo Group Limited (GB) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012076435-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2 | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |